# Abstract

 

## Objective: The objective of this study is to examine the impact of vary doses of buprenorphine on anxiety symptoms in opioid-dependent inpatients over a 7 days period, using a randomized controlled trial design. 

## Design: Patients were randomized to three groups. 

## Patients and Methods: Fourteen men who met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for both opioid use disorder and generalized anxiety disorder and were seeking for treatment. 

## Intervention: Patients obtain dosages of 32 mg or 64 mg or 96 mg of buprenorphine as a single dose only and were treated in a psychiatric inpatient unit. Of 14 subjects; 5 (35.7%) obtained 32 mg, 4 (28.6%) obtained 64 mg, and 5 (35.7%) obtained 96 mg of buprenorphine. 

## Measurements: Administering daily Hamilton Anxiety Rating Scale and interview. 

## Results: All the patients ended the 7-day treatment time. The results showed a significant reduction in anxiety symptoms within each of the three groups ( *P* = 0.00), but no difference in outcome between the groups ( *P* = 0.605). 

## Conclusions: The outcome suggests a single high dose of buprenorphine can supply a speedy, safe, simple, and suitable means of anxiety treatment. The single high dose of buprenorphine could be a novel mechanism medication that provides a rapid and sustained improvement for generalized anxiety disorder in opioid dependent patients. Placebo-controlled trials of longer duration are needed to evaluate ability, safety, and psychological and physiological influence of extended exposure to this medication. # RESULTS All the 14 inpatients completed the 7-day period study. Hence, the data were gathered from 14 male opioid dependents whose mean age was 31.87 ± 8.15 year; with age range of 17--48 years. Out of 14 patients; 5 (35.7%) obtained 32 mg, 4 (28.6%) obtained 64 mg and also 5 (35.7%) obtained 96 mg of buprenorphine. Regarding marital status, age, education, and employment, we could not find any statistically significant differences in groups. [Table 1](#)demonstrates demographic features of the patients. As we note, there are not any significant differences in their demographic features. ::::table-wrap

::: caption
Demographic characteristics of 14 subjects
:::

![](<>):::: [Table 2](#)represents anxiety scores of the groups during 7 days of treatment time. As we look in 32-mg group, we note that there are significant statistical differences in anxiety scores between day 1 and day 7 ( *P* = 0.001). Similarly, there are significant differences in anxiety scores between day 1 and day 7 both in 64-mg group ( *P* = 0.000) and 96-mg group ( *P* = 0.00). ::::table-wrap
::: caption
Hamilton Anxiety Rating Scale
:::

![](<>):::: Comparing the mean anxiety scores in three groups, we cannot see any significant differences. [Figure 1](#)portrays the anxiety scores from day 1 to day 7 in all groups. <figure> <p><img src="" /></p> <figcaption>Hamilton Anxiety Rating Scale</figcaption> </figure>


Extracted trial result:
Outcome: Anxiety (continuous)
Intervention: Buprenophine 32 mg
Comparator: Buprenophine 96 mg
Intervention group size: 5
Comparator group size: 5
Notes: found in table